Industry News
Neuralink adds chronic stroke to a new US implant trial
Neuralink has registered PRIME2, a US early feasibility study of its N1 implant that adds people with chronic ischaemic stroke to those with spinal cord injury and ALS. Up to 10 participants at up to five US sites will use the implant to control a computer cursor or virtual keyboard, starting at the University of Miami. The first version of the registry entry required a stroke at least 12 months before screening with lasting weakness in the arm that was dominant before it; a version posted two days later shortened the criteria. Stroke affects far more people than the conditions Neuralink's first US trial covered.